BC Extra | Nov 17, 2018
Preclinical News

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

Spotlight Therapeutics Inc. (Hayward, Calif.) co-founder Alexander Marson and colleagues at University of California San Francisco developed a CRISPR-based screen to identify genes that control T cell replication and immunosuppression, and used the results to...
BC Innovations | May 20, 2010
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Cas-Br-M ecotropic retroviral transforming sequence b (CBLB) Genomewide association studies have identified a SNP that could help predict the risk of...
BC Innovations | Oct 15, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cas-Br-M ecotropic retroviral transforming sequence b (CBLB) Studies in murine cells and in mice suggest that inhibiting CBLB could boost the activity of NK...
BC Week In Review | Jan 22, 2007
Company News

Cleveland BioLabs, Roswell Park Cancer Institute deal

CBLI will receive about $3 million from the institute and up to $2 million from other New York state agencies toward development of the company's CBLC 102 to treat cancer and CBLB 502 and CBLB...
Items per page:
1 - 4 of 4